Brain proteomic changes by histone deacetylase inhibition after traumatic brain injury

BACKGROUND: Traumatic brain injury (TBI) is a leading cause of morbidity and mortality. There are currently no cytoprotective treatments for TBI. There is growing evidence that the histone deacetylase inhibitor valproic acid (VPA) may be beneficial in the treatment of TBI associated with hemorrhagic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Trauma Surg Acute Care Open
Autors principals: Pumiglia, Luke, Williams, Aaron M, Kemp, Michael T, Wakam, Glenn K, Alam, Hasan B, Biesterveld, Ben E
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7993337/
https://ncbi.nlm.nih.gov/pubmed/33880414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/tsaco-2021-000682
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars